Accurius Prepares for Major Fundraising Round

Biopharma startup Accurius has announced plans to raise $7 million in funding to advance its novel anti-cancer therapy. The company is positioning India as a key hub for clinical trials and large-scale manufacturing, thanks to its strong medical infrastructure and cost-effective operations.

Clinical Trials Across Three Continents

According to CEO Srivatsan, Accurius is currently exploring trial sites in India, Australia, and the United States. A pre-IND (Investigational New Drug) meeting with the US Food and Drug Administration (USFDA) is expected within six months of closing the funding round. Phase 1 trials will enroll 15–30 patients, focusing on cancers localized in the lungs, including non-small cell lung cancer and metastatic tumors.

India’s Role in Cancer Research

India has become an increasingly attractive destination for global biotech firms conducting clinical trials. Its large patient pool, skilled medical workforce, and growing pharmaceutical industry make it a strategic choice for Accurius. Trivia cue: India is among the world’s largest producers of generic medicines, supplying nearly 20% of global demand.

What Makes This Therapy Novel?

Accurius’ therapy aims to address the challenges of current cancer treatments by offering a more targeted approach. Unlike conventional chemotherapy that impacts both healthy and cancerous cells, this therapy is designed to localize treatment and reduce side effects, potentially improving patient quality of life during cancer care.

Next Steps and Global Impact

If successful, this therapy could transform how cancers such as lung cancer are treated worldwide. By combining innovation with India’s cost-efficient ecosystem, Accurius hopes to accelerate availability and affordability of advanced treatments. Early success in Phase 1 trials could pave the way for expanded trials and eventual regulatory approvals across multiple regions.

Takeaway

With cancer being one of the world’s leading causes of death, initiatives like Accurius’ are vital. This $7 million fundraising effort not only marks a step forward for the company but also highlights India’s rising role in the global biotech landscape.

Source: Moneycontrol